{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:30:34Z","timestamp":1761093034323,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.urolonc.2021.01.018","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T02:03:15Z","timestamp":1616119395000},"page":"277-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HIF2 Inhibition for von-Hippel Lindau Associated Kidney Cancer: Will Urology Lead or Follow?"],"prefix":"10.1016","volume":"39","author":[{"given":"Brian","family":"Shuch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.01.018_bib0001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/ejhg.2016.173","article-title":"Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark","volume":"25","author":"Binderup","year":"2017","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0002","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0003","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1086\/302726","article-title":"Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents","volume":"66","author":"Sgambati","year":"2000","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0004","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","article-title":"Von Hippel-Lindau disease: a genetic study","volume":"28","author":"Maher","year":"1991","journal-title":"J Med Genet"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0006","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0007","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0022-5347(01)67318-X","article-title":"Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study","volume":"153","author":"Steinbach","year":"1995","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0008","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF00182972","article-title":"Enucleation procedures in patients with multiple hereditary renal tumors","volume":"13","author":"Walther","year":"1995","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0009","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0022-5347(17)32285-1","article-title":"Evaluation of color Doppler intraoperative ultrasound in parenchymal sparing renal surgery","volume":"152","author":"Walther","year":"1994","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/01.ju.0000132127.79974.3f","article-title":"The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease","volume":"172","author":"Duffey","year":"2004","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0011","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0022-5347(05)68930-6","article-title":"Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery","volume":"161","author":"Walther","year":"1999","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0012","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MOU.0b013e32834964ea","article-title":"Repeat partial nephrectomy: surgical, functional and oncological outcomes","volume":"21","author":"Shuch","year":"2011","journal-title":"Current opinion in urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0013","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0022-5347(05)67634-3","article-title":"A phase 2 study of radio frequency interstitial tissue ablation of localized renal tumors","volume":"163","author":"Walther","year":"2000","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0014","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrurol.2012.174","article-title":"Kidney cancer: Is incomplete renal ablation linked to tumour progression?","volume":"9","author":"Shuch","year":"2012","journal-title":"Nat Rev Urol"},{"issue":"15_suppl","key":"10.1016\/j.urolonc.2021.01.018_bib0015","doi-asserted-by":"crossref","first-page":"4584-","DOI":"10.1200\/jco.2013.31.15_suppl.4584","article-title":"Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma","volume":"31","author":"Stamatakis","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0016","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10689-014-9771-y","article-title":"First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response","volume":"14","author":"Roma","year":"2015","journal-title":"Fam Cancer"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0017","doi-asserted-by":"crossref","first-page":"85306","DOI":"10.18632\/oncotarget.13301","article-title":"Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group","volume":"7","author":"Oudard","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0018","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1093\/annonc\/mdr011","article-title":"Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease","volume":"22","author":"Jonasch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0019","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0021","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(18)30487-X","article-title":"Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial","volume":"19","author":"Jonasch","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0022","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.94.15.8104","article-title":"Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth","volume":"94","author":"Maxwell","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0023","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1535-6108(02)00043-0","article-title":"Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein","volume":"1","author":"Kondo","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0025","doi-asserted-by":"crossref","first-page":"9361","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Molecular and cellular biology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0026","doi-asserted-by":"crossref","first-page":"29936","DOI":"10.1074\/jbc.M204733200","article-title":"Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway","volume":"277","author":"Isaacs","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0027","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/1078-0432.CCR-06-2966","article-title":"Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells","volume":"13","author":"Xu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0028","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1073\/pnas.0808092106","article-title":"Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor","volume":"106","author":"Scheuermann","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0029","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0030","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0031","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2alpha Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0032","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","article-title":"3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzo nitrile (PT2977), a Hypoxia-Inducible Factor 2alpha (HIF-2alpha) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma","volume":"62","author":"Xu","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0033","doi-asserted-by":"crossref","first-page":"5003-","DOI":"10.1200\/JCO.2020.38.15_suppl.5003","article-title":"Phase II study of the oral HIF-2\u03b1 inhibitor MK-6482 for Von Hippel-Lindau disease\u2013associated renal cell carcinoma","volume":"38","author":"Jonasch","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2021.01.018_bib0034","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-19-1459","article-title":"HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma","volume":"26","author":"Courtney","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:01Z","timestamp":1761042061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1078143921000247"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIF2 Inhibition for von-Hippel Lindau Associated Kidney Cancer: Will Urology Lead or Follow?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}